{"entity":{"id":"idea-tr2-spatial-biomarker-standards","kind":"idea","name":"Standards for spatial and multiplex tissue biomarkers before they reach the clinic","aka":[],"tldr":"New microscopes can measure dozens of proteins at once and map where immune cells sit in a tumour. These readouts could predict immunotherapy response, but every lab does it differently.","summary":"Multiplex immunofluorescence and spatial transcriptomics generate spatial biomarkers (immune cell distances, niches, tertiary lymphoid structures) with strong retrospective association to immunotherapy outcome. Platforms, panels, segmentation and metrics are not standardised, so no spatial biomarker has reached clinical validation. A consortium defining minimal reporting, reference tissue, shared segmentation benchmarks and a core panel would let spatial biomarkers be compared across studies and taken into prospective trials.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Biomarkers are not validated or standardised): Fernandez et al., Examination of low ERBB2 protein expression in breast cancer tissue (JAMA Oncology 2022)","url":"https://doi.org/10.1001/jamaoncol.2021.7239"}],"tags":[],"related":["10x-genomics"],"cancers":[],"sections":[],"technologies":["single-cell-spatial","digital-pathology-ai"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["tils","cold-vs-hot"],"trials":[],"people":[],"bottlenecks":["b-biomarker-validation","b-immunotherapy-response"],"keyPapers":["paper-fernandez-jama-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A standardised spatial immune score will predict PD-1 blockade response with an area under the curve above 0.75 across two independent cohorts run on different platforms, exceeding PD-L1 IHC.","rationale":"Multi-institutional meta-analyses find spatial features outperform PD-L1 in retrospective data; lack of standards, not lack of signal, blocks translation.","test":"Run a multi-site ring study on the same tissue blocks across platforms; define the reproducible feature set; validate prospectively in an immunotherapy trial.","maturity":"preclinical-evidence","actor":"research","cost":"medium","horizonYears":4},"route":"/ideas/idea-tr2-spatial-biomarker-standards/","neighbours":{"company":[{"id":"10x-genomics","kind":"company","name":"10x Genomics","route":"/companies/10x-genomics/"}],"technology":[{"id":"digital-pathology-ai","kind":"technology","name":"Digital pathology & AI","route":"/technologies/digital-pathology-ai/"},{"id":"single-cell-spatial","kind":"technology","name":"Single-cell & spatial profiling","route":"/technologies/single-cell-spatial/"}],"term":[{"id":"cold-vs-hot","kind":"term","name":"Hot vs cold tumours","route":"/terms/cold-vs-hot/"},{"id":"tils","kind":"term","name":"Tumour-infiltrating lymphocytes (TILs)","route":"/terms/tils/"}],"bottleneck":[{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/"},{"id":"b-immunotherapy-response","kind":"bottleneck","name":"No one can predict who responds to immunotherapy","route":"/bottlenecks/b-immunotherapy-response/"}],"paper":[{"id":"paper-fernandez-jama-oncol","kind":"paper","name":"Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue","route":"/key-papers/paper-fernandez-jama-oncol/"}]}}